COMMENTARY

COVID-19 Data, Fast and Furious: 'We Need to Adapt'

F. Perry Wilson, MD, MSCE

Disclosures

March 30, 2020

Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

This transcript has been edited for clarity.

Hi folks.

On February 9, 2020, I made a video talking about how epidemiologists think of infectious disease. My goal was to put some intuition behind the numbers we'd all been hearing. At that time, there were 40,150 documented cases of COVID-19 worldwide. There were 11 cases in the United States.

It's been about 6 weeks, and the world is nearly unrecognizable.

When I made that video, the problem felt abstract: Here was an educational opportunity, not a threat to our very way of life. I tried to place the novel coronavirus amid other infectious diseases, using epidemiologic calculations. I went on to talk about how that 2% case fatality rate is probably wrong, since we're not testing enough people; as we test people who are less symptomatic, it won't look as bleak.

Also, as we get better at social distancing, that "contagiousness," the R0 number, would go down, limiting spread.

I have been watching for these trends over the past month and a half. Where are we?

I used the same data that the Johns Hopkins team uses for their incredible COVID-19 tracker to get these case fatality rates over time.


 

That's... not what I wanted to see. As testing increased, I was confident we'd see this number fall more. I still hold on to the hope that these numbers will lag testing increases, but I need to admit that I'm very concerned that it hasn't fallen at all. South Korea, paragon of testing and reporting in this worldwide crisis, has a case fatality rate as of this reporting of just over 1%. The US is at 1.3%. If that number holds steady, we really may see more than a million deaths in this country.

What about the R0, originally thought to be around 2.5? Or, in other words, the average infected person would spread the virus to 2.5 other people, leading to exponential growth. Social distancing—limiting contacts—was our major intervention to reduce the R0. How is that going?

We don't know yet. This log-scale graph of infections in the United States keeps going straight up. But again, there is a lag between infection and symptoms, so maybe we'll start to bend this curve soon.


 

We've also learned that we got some things wrong in those halcyon days of early February.

Based on data from China, we assumed that the virus was relatively benign in young people without comorbidities. This may not be true.


 

CDC data from last week shows around a 20% hospitalization rate for people I'd consider "young"—in that 20-44 years age group. Case fatality rate is still low there at 0.1%-0.2%, which is encouraging. But clearly, this is not just a bad cold for these kids.

We also thought that fever was a central symptom in COVID-19 and focused (and continue to focus) testing on those with demonstrable fever. Yet case series and cohort studies are showing that an elevated temperature is not the rule in this disease.


 

And while the most severe cases do develop pulmonary disease, many do not present with respiratory symptoms.

Data are coming fast and furious, and we need to be able to adapt our conceptions about this disease quickly. For example, the use of fever to triage available testing may not be the best choice. Respiratory symptoms are not the sine qua non we think they are, at least initially. We need to have the flexibility to try new therapies and abandon them when we find that they are ineffective.

And, of course, we need to protect our healthcare workers. Because vents only work when you have someone to run them.

I'll check in with you as more data come out and we revise these critical numbers further.

F. Perry Wilson, MD, MSCE, is an associate professor of medicine and director of Yale's Program of Applied Translational Research. His science communication work can be found in the Huffington Post, on NPR, and here on Medscape. He tweets @methodsmanmd and hosts a repository of his communication work at www.methodsman.com.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....